These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27576691)

  • 1. Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.
    Banuelos CA; Tavakoli I; Tien AH; Caley DP; Mawji NR; Li Z; Wang J; Yang YC; Imamura Y; Yan L; Wen JG; Andersen RJ; Sadar MD
    J Biol Chem; 2016 Oct; 291(42):22231-22243. PubMed ID: 27576691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
    Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
    J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
    Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
    Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of niphatenones that inhibit androgen receptor N-terminal domain.
    Banuelos CA; Lal A; Tien AH; Shah N; Yang YC; Mawji NR; Meimetis LG; Park J; Kunzhong J; Andersen RJ; Sadar MD
    PLoS One; 2014; 9(9):e107991. PubMed ID: 25268119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.
    Andersen RJ; Mawji NR; Wang J; Wang G; Haile S; Myung JK; Watt K; Tam T; Yang YC; Bañuelos CA; Williams DE; McEwan IJ; Wang Y; Sadar MD
    Cancer Cell; 2010 Jun; 17(6):535-46. PubMed ID: 20541699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.
    Fancher AT; Hua Y; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2019; 17(8):364-386. PubMed ID: 31502857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain.
    Hua Y; Azeem W; Shen Y; Zhang S; Olsen JR; Øyan AM; Ke X; Zhang W; Kalland KH
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00437. PubMed ID: 30410767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
    Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
    Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
    J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC.
    Ji Y; Zhang R; Han X; Zhou J
    Eur J Med Chem; 2023 Feb; 247():115077. PubMed ID: 36587421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor.
    Sadar MD
    Expert Opin Drug Discov; 2020 May; 15(5):551-560. PubMed ID: 32100577
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer.
    Obst JK; Tien AH; Setiawan JC; Deneault LF; Sadar MD
    Steroids; 2024 Oct; 210():109482. PubMed ID: 39053630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer.
    Thiyagarajan T; Ponnusamy S; Hwang DJ; He Y; Asemota S; Young KL; Johnson DL; Bocharova V; Zhou W; Jain AK; Petricoin EF; Yin Z; Pfeffer LM; Miller DD; Narayanan R
    Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211832120. PubMed ID: 36577061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
    Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.
    Antonarakis ES; Chandhasin C; Osbourne E; Luo J; Sadar MD; Perabo F
    Oncologist; 2016 Dec; 21(12):1427-1435. PubMed ID: 27628492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
    Ponnusamy S; Coss CC; Thiyagarajan T; Watts K; Hwang DJ; He Y; Selth LA; McEwan IJ; Duke CB; Pagadala J; Singh G; Wake RW; Ledbetter C; Tilley WD; Moldoveanu T; Dalton JT; Miller DD; Narayanan R
    Cancer Res; 2017 Nov; 77(22):6282-6298. PubMed ID: 28978635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.